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Abstract
Long-lasting HBV-DNA suppression is considered to be the best surrogate
end-point of antiviral therapy in patients with hepatitis B virus (HBV)
related chronic hepatitis or cirrhosis, and it is a prerequisite to prevent liver-
related complications and improve survival. Treatment with oral antiviral
drugs in patients with HBV cirrhosis is effective in restoring liver function
and improving survival even in those with decompensated cirrhosis. These
agents are generally well-tolerated for long-term treatment, and several evi-
dences have demonstrated that they are able to reverse liver fibrosis and pre-
vent the occurrence of HCC.2
In patients with HBV related cirrhosis, antiviral therapy
with nucleoside or nucleotide analogues (NAs) should
be initiated as soon as the diagnosis has been estab-
lished. European Association for the Study of the Liver
(EASL) Clinical Practice Guidelines (1) suggest that an-
tiviral treatment of HBV cirrhosis is indicated to pre-
vent viral reactivation whatever the serum HBV-DNA
levels.
In fact, there is a significant correlation between HBV
DNA levels and necroinflammatory activity (2) and
since liver fibrosis is mainly stimulated by hepatic necr-
oinflammatory activity (3), the fibrogenetic process
could be reduced as a result of the suppression of HBV.
The main goals of antiviral therapy are to prevent
liver decompensation, the occurrence of hepatocellular
carcinoma (HCC) and to improve survival. However,
numerous studies have been performed to assess the
progressive changes in liver histology with long-term
antiviral therapy. Indeed, even if this is only a surrogate
outcome it could help improve the prognosis of HBV
related liver damage.
Although advanced liver fibrosis was previously
thought to be irreversible, there is evidence to show that
cirrhosis can be reversed if the underlying cause of liver
injury is eliminated (4–14). The purpose of this review
is to collect the available data from literature focusing
the issue of reversibility of liver fibrosis after antiviral
therapy in Chronic Hepatitis B.
Natural course of chronic HBV infection
The natural history of chronic HBV infection and dis-
ease is complex, thus understanding the clinical out-
comes and the factors affecting disease progression is
important in the management of this entity (15). Fatto-
vich et al. (16) performed a systematic review in 2008
assessing the rate of disease progression and the factors
influencing the course of liver disease.
The 5-year cumulative incidence of cirrhosis was 8
and 17% in East Asian countries and European coun-
tries, respectively, in patients with HBeAg positive
chronic hepatitis and 13 and 38%, respectively, in
patients with HBeAg negative chronic hepatitis. When
they present with compensated cirrhosis at least 30–70%
of patients still have active viral replication, which is
associated with continued liver disease progression and
decreased survival over time (17, 18).
Among host factors, older age is an important deter-
minant of progression to cirrhosis and HCC since it is
related to a longer duration of HBV liver disease. Male
gender has been also identified as an independent risk
factor of cirrhosis (19, 20) and the overall risk of HCC
L I V 1 2 3 9 5 Dispatch: 26.11.13 CE: Malarvizhi
Journal Code Manuscript No. No. of pages: 6 PE: Prasanna
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
Liver International (2013)
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 1
Liver International ISSN 1478-3223
in chronic HBV carriers is three to six times higher in
men than in women (21, 22). The antifibrogenic effect
of oestrogen probably explains this association (23).
The incidence of hepatic decompensation and/or
oesophageal varices bleeding was 3–4 per 100 person
years in patients with early stages of cirrhosis in both
European and Asian studies, with a 5-year cumulative
incidence of liver decompensation of 15% (5, 24–26).
Decompensation usually presents with at least one
episode of ascites, jaundice, hepatic encephalopathy or
variceal bleeding (27). This can develop insidiously or as
a complication of an acute hepatitis flare (28). The latter
was demonstrated in a study showing that hepatic
decompensation developed in 14% of patients with cir-
rhosis who experienced hepatitis flares (29). The prog-
nosis of these two modes of hepatic decompensation
have not been clearly differentiated and compared.
Other hepatitis virus superinfections in HBV patients
with cirrhosis other than active HBV replication could
cause decompensation (16, 30).
Once hepatic decompensation occurs, mortality
increases significantly, ranging from 70 to 85% at 5-year
follow-up in different studies (25, 31). These patients
need to be carefully evaluated. Evaluation of patients
with cirrhosis includes liver function status, and the
presence of varices. Monitoring of HCC in patients with
HBV cirrhosis is mandatory.
The efficacy of antiviral therapy in patients with
HBV cirrhosis
Therapy must provide sufficient virological suppression
to achieve biochemical remission, histological improve-
ment and the prevention of complications. The ideal out-
come is HBsAg loss which unfortunately is infrequent.
Moreover, complete eradication of hepatitis B virus
(HBV) infection in chronic hepatitis B is not achieved
with current therapies. Even in patients who clear
HBsAg, HBV remains in infected hepatocytes in the form
of covalently closed circular DNA (cccDNA) for the life-
time of the cell, thus, a more realistic goal of therapy is
sustained or maintained virological remission (32).
Drugs available for the treatment of CHB include
interferon (IFN), PEG-IFN and five NAs. NAs for HBV
therapy can be classified into nucleosides (lamivudine,
LAM; telbivudine, TBV; entecavir, ETV) and nucleo-
tides (adefovir, ADV; tenofovir, TFV).
Interferon based therapy
Interferon based therapy is not frequently used in
patients with cirrhosis. Indeed, even if it has certain
advantages such as finite duration, the absence of resis-
tance and higher rates of anti-HBe and anti-HBs sero-
conversion, there is only a moderate antiviral effect,
poor tolerability and a high risk of adverse events (1).
Thus, there is not enough evidence to determine the
histological improvement of patients with HBV related
cirrhosis following IFN. However, numerous studies
have shown how conventional IFN therapy or more
recently PEG-IFN can reduce the progression of fibrosis
and the occurrence of liver decompensation and HCC
both in HBeAg positive and HBeAg negative patients
(33–37). A significant reduction in the incidence of cir-
rhosis (17.8% vs 33.7% in the controls; P = 0.041) has
been demonstrated (33) in a large cohort of HBeAg-
positive patients treated with IFN compared with well-
matched untreated patients.
Furthermore, an earlier randomized control study
showed that IFN therapy reduced the incidence of HCC
in patients with HBeAg-positive active chronic hepatitis
(34).
Moreover, HBeAg-negative patients who achieved a
sustained viral response (SVR) following IFN showed a
decrease in the progression of the Ishak fibrosis score or
a decreased risk of cirrhosis as well as fewer severe cir-
rhosis-related complications in the long term, a reduced
incidence of HCC, less need for liver transplantation
and lower mortality. Unfortunately, a SVR occurred in
less than 30% of HBeAg-negative patients (35, 36).
Interferon-based therapy has been shown to be safe
in patients with compensated cirrhosis (37) also sug-
gesting that patients with cirrhosis can benefit from IFN
based treatment.
A recently published meta-analysis showed a signifi-
cant reduction in the risk of HCC ranging from a 34%
reduction in patients with chronic hepatitis to 47% in
patients with cirrhosis (38). Two other meta-analyses
have confirmed that IFN therapy significantly prevented
the development of HCC. (10, 39).
Nucleoside and nucleotide analogues
Five different antiviral agents have been approved and
treatment with these oral agents has been shown to be
life-saving. LAM and ADV and more recently ETV 3),
TBV and TFV have revolutionized the treatment of
chronic hepatitis B (40). These treatments can delay the
progression of fibrosis and reverse both fibrosis and cir-
rhosis (3, 4, 7, 8), Table 1. Furthermore, they prevent
hepatic decompensation in patients with advanced
fibrosis and cirrhosis (5, 41, 42).
Lamivudine
LAM was the first oral agent licensed for the treatment
of hepatitis B. Clinical trials have shown that LAM ther-
apy can delay the progression of fibrosis, reduce pro-
gression to and reverse cirrhosis, prevent liver
decompensation in patients with cirrhosis and stabilize
patients with hepatic decompensation (4, 5, 43).
In a study from Asia (5), continuous LAM therapy
delayed clinical progression in CHB patients and
advanced fibrosis or cirrhosis by reducing the incidence
of hepatic decompensation and HCC. Similarly, an Ital-
ian multicentre study designed to evaluate the clinical
Liver International (2013)
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outcome of chronic HBV in relation to virological
response to LAM (41) found that HBeAg-negative
patients with cirrhosis and with a SVR were less likely
than those with viral breakthrough to develop HCC and
disease progression, and that survival was better in
patients with Child A cirrhosis and SVR.
The direct effect of LAM monotherapy on portal
pressure in CHB cirrhosis was evaluated in a prospective
study by Manolakopoulos et al. (42). The results of this
study show that virological and biochemical response to
LAM is associated with a significant decrease in portal
pressure in patients with cirrhosis and clinically signifi-
cant portal hypertension (hepatic venous pressure gradi-
ent >10 mmHg).
Although LAM has the most extensive safety record,
the high rate of viral breakthrough because of virological
resistance to LAM (up to 30% in year 1 and up to 70%
at the end of 5 years) and the availability of more potent
and effective agents with improved resistance profiles,
has reduced its use in patients with chronic hepatitis B
especially those with cirrhosis in whom loss of virologi-
cal response can lead to clinical deterioration.
Adefovir dipivoxil
Although ADV is less potent than LAM, it has mainly
been used for LAM-resistant chronic hepatitis B and
hepatic decompensation associated with LAM-resistance
prior to and after liver transplantation (1, 44). Indeed,
the advantage of this drug was its limited resistance for
1–2 years and the absence of cross-resistance with LAM
and other L-nucleosides. Long-term (>3 years) ADV
therapy resulted in the improvement of fibrosis or the
reversal of advanced fibrosis (6, 9). Marcellin et al. (9)
have shown a significant histological improvement
(defined as a reduction of at least 2 points in the Kno-
dell necroinflammatory score with no worsening of the
Knodell fibrosis score) in 60% of patients treated with
ADV and with liver biopsy before and after antiviral
therapy. Hadziyannis et al. (6) observed a significant
improvement in liver histology following long-term
treatment with ADV.
In this large trial, liver biopsies after 192 (placebo-
ADV group) or 240 weeks (ADV group) of treatment
showed that necroinflammation improved in 86% and
83% of patients, respectively, and fibrosis improved in
73 and 75%, respectively, compared with pretreatment
biopsies.
In a long-term follow-up study of the 226 waiting list
patients and 241 post-transplant patients with recurrent
hepatitis B because of LAM-resistant HBV, the use of
ADV resulted in undetectable HBV DNA in 65% of the
waiting list and post-transplant patients after 96 weeks
of therapy. Moreover, after 48 weeks of treatment, liver
function improved in 50–80% of these patients (44).
Like LAM this drug has been gradually replaced by
more recent NAs because of the resistant variants that
increase after the first year and reach almost 30% after
4 years (1).
Entecavir
Entecavir (ETV) is a potent inhibitor of viral replication
in chronic hepatitis B. In a recent study, an Italian group
evaluated the efficacy of ETV in an Italian cohort of
unselected patients with different stages of liver fibrosis,
comparing the virological and clinical results between
patients with and without cirrhosis (45 4). This study
showed that results with ETV were excellent for patients
with HBV liver disease and especially cirrhosis where
there was a good tolerability profile, better efficacy and
an earlier virological response.
Schiff et al. (11) evaluated the improvement in liver
histology in 10 patients with advanced fibrosis or
Table 1. Rate of the regression of fibrosis in patients with chronic hepatitis B and cirrhosis treated with nucleos(t)ide analogues.
Patient N. HBsAg status Regression of fibrosis Reference
1 2 3 5 (yr)
Lamivudine 30 + 67% 4
Adefovir 16  75% 6
15 + 60% 9
90/125 ± 49%/12% 49
Entecavir 10 ± 100% 11
57 ± 96% 12
(10*) 40% 100%
Tenofovir 133 ± 27% 68% 14
(96*) ± 74% 49
176/250 71%/67%
Telbivudine 921/446 ± 65%/67% 51
*Patients with cirrhosis
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cirrhosis (Ishak fibrosis score 4–6), who received long-
term ETV treatment (approximately 6 years, range,
267–297 weeks). All patients had liver biopsies at base-
line, week 48, and long term, and histological improve-
ment of at least 1-point on the Ishak fibrosis score was
found in all patients after long-term treatment. Simi-
larly, in a study by Chang et al. (12), 96% of patients
(55/57) had histological improvement after long-term
treatment with ETV. Ten of the 57 patients had
advanced fibrosis or cirrhosis (Ishak score 4–6) at the
baseline. All 10 patients achieved at least a 1-point
reduction in the Ishak fibrosis score after long-term
ETV therapy.
Also there was a 6.37-point reduction in the mean
Knodell necroinflammatory score after long-term treat-
ment vs a mean reduction of 3.39 points after 48 weeks
of ETV therapy.
A more recent study analysing 372 ETV-treated
patients including 98 patients with cirrhosis, showed
that the virological response to ETV is associated with a
lower probability of disease progression (liver decom-
pensation and HCC) in patients with cirrhosis (13).
Finally, Shim et al. (46) prospectively compared the
efficacy of ETV in 70 patients with decompensated cir-
rhosis and 144 patients with compensated CHB. There
was no significant difference between the groups in the
percentage of patients who achieved undetectable HBV
DNA or ALT normalization and HBeAg seroconversion
or HBeAg loss after 6 or 12 months of treatment. The
Child–Pugh score (CPS) and the Model for End Liver
Disease (MELD) score was significantly improved in de-
compensated patients treated for >12 months and the
2-year cumulative rates of HCC and death or liver trans-
plantation were 6.9 and 17% respectively.
Tenofovir
TFV, the most recently approved drug for hepatitis B, is
more potent, more rapid and has a better resistance pro-
file than ADV as well as an excellent safety profile. There
are very few data on the outcome of patients with cir-
rhosis and TFV.
In the study by Marcellin et al. (47), histological
improvement was obtained in significantly more
patients who received TFV than in those who received
ADV (71% vs. 49% in HBeAg-negative patients and
67% vs. 12% in HBeAg- positive patients). Necroin-
flammation was reduced in most patients. More
recently, another study evaluated the histological
improvement (≥2 point reduction in Knodell necroin-
flammatory score with no worsening of fibrosis) and
regression of fibrosis (≥1 unit decrease by Ishak scor-
ing system) in a large cohort of patients treated with
TFV (14). At baseline 38% (133/348) of the patients
had bridging fibrosis to cirrhosis (Ishak scores of 4 or
more), but this rate declined to 28% (97/344) and
12% (42/348) at year 1 and year 5 respectively. Over-
all, the regression of fibrosis occurred in 51% (176/
348) of patients and histological improvement in 304/
348 (87%) of patients after 5 years of treatment.
Figure 1.
Finally a 2 point reduction in the CPS occurred in
48% of patients with liver decompensation treated with
TFV compared with 41.7% treated with ETV, and a
median reduction in the MELD score of 2.0 from base-
line was reported for both groups (48).
Telbivudine
There are only few data evaluating the real effects of
TBV on histological improvement in patients with
chronic hepatitis B. In HBeAg-positive patients, TBV
seems to be better than LAM in achieving histological
improvement (65% vs 56%) but not in obtaining bio-
chemical (77% vs 75%) or serological responses (HBeAg
seroconversion in 23% vs 22%). On the contrary, in
HBeAg-negative patients, TBV suppressed HBV DNA to
undetectable levels in 88% of patients vs 71% of patients
treated with LAM but histological improvement (67%
vs 66%) and biochemical improvement (74% vs 79%)
was not different between the two groups (49).
Conclusion
The goal of treatment for chronic HBV infection is to
achieve viral suppression, control liver fibrosis and pre-
vent progression to hepatic decompensation and HCC.
Hepatic fibrosis is mainly stimulated by hepatic necro-
inflammatory activity, and several studies have shown
that prolonged antiviral therapy is associated with
improvement in liver histology and even reversal of cir-
rhosis in chronic HBV infection.
Figure 1. 10Histological response at year 5 according to baseline
Ishak fibrosis scores for 348 patients with data available at baseline
and year 5 (Marcellin P, Lancet 2013;381: 468–75).
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However, the evidences available so far, involved a
small proportion of patients enrolled in the trials, and
consisted of a small number of patients with advanced
fibrosis or cirrhosis. Moreover, there is the bias because
of selection of patients to undergo repeat biopsy and
furthermore the important issue of the correct stain for
elastic fibres in liver biopsies. Indeed, mostly in presence
of high grade of necroinflammation, there is a paren-
chymal collapse simulating septa, and in these cases col-
lagen stains (Sirius Red, Masson Thricrome) could lead
to a misdiagnosis of cirrhosis which could be evaluated
as disappeared in the successive liver biopsies.
In our opinion the amount of liver fibrosis, if cor-
rectly evaluated, could be reduced by a switching off of
inflammation but we need more and well-designed
studies to assess whether the distorted liver parenchyma
and altered blood flow in the cirrhotic liver are revers-
ible.
This review has provided an update on these data. All
NAs have been shown to improve liver histology in
patients with CHC and this is especially true in patients
with advanced fibrosis. Improvement in both necroin-
flammation and the stage of fibrosis prevents decom-
pensation and HCC, significantly changing the
prognosis of patients with HBV cirrhosis. For this rea-
son both patients with compensated and decompensat-
ed cirrhosis should be promptly and correctly treated
with oral antiviral therapy whatever the HBV DNA level
as early as possible (Fig. 1).
Available antiviral drugs are safe and effective in
improving liver function in this population although
only the use of ETV and TFV is highly recommended
because of their low risk of resistance.
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